FDA Brief

Warning letters Drugs

FDA warning letter to

RAAS Nutritionals, LLC/Rare Antibody Antigen Supply, Inc.

High riskIssued Sep 30, 2021Posted Oct 12, 2021Center for Drug Evaluation and Research | CDER

FDA says RAAS Nutritionals ran human drug studies without required IND applications, despite claiming products were dietary supplements.

What happened

FDA inspected RAAS from March 15 to 23, 2021, and reviewed the company’s April 7, 2021, response. FDA found that RAAS started and ran three clinical investigations of investigational drug products without submitting an IND (an investigational new drug application) or having one in effect. FDA said the products were drugs in these studies because they were studied to cure, mitigate, or treat disease, even though RAAS called them dietary supplements.

What FDA found

  1. RAAS started clinical investigations of investigational drugs in people without submitting an IND to FDA and having it in effect first.

    21 CFR 312.20(a), 312.20(b), and 312.40(a)
  2. FDA says these studies did not qualify for any exemption from the IND requirements.

    21 CFR 312.2
  3. FDA treated the products as drugs in these studies because they were studied to cure, mitigate, or treat disease.

    FD&C Act section 201(g)(1) [21 U.S.C. 321(g)(1)]
  4. RAAS’s written response did not provide a corrective action plan for complying with IND rules.

What FDA wants

Within 15 business days of receiving the letter, RAAS must notify FDA in writing of actions it has taken to prevent similar violations. If it believes it complied, it must include its reasoning and supporting information.

Who should pay attention

  • sponsors and contract research organizations running clinical trials
  • IRBs and clinical sites reviewing supplement or botanical studies
  • companies that sell supplements and describe drug-like benefits

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Jose M. Carpio, M.D.

    FDA warned clinical investigator Dr. Jose Carpio of Miami Lakes, FL, that trial subjects received less than the protocol-required dose of study drug.

    Medium
  2. Mukesh B. Chandre, M.D., MBBS/Ashirwad Hospital & Research Centre

    FDA warned clinical investigator Dr. Mukesh Chandre over informed consent failures in a doxorubicin liposome bioequivalence study.

    High risk
  3. Ehsan Sadri, M.D.

    FDA warns Dr. Ehsan Sadri that two ineligible subjects received an investigational drug in clinical trials.

    High risk
  4. Center For Immunology Science, LLC

    FDA cites Center for Immunology Science for a clinical trial of heat-killed Mycobacterium smegmatis without an Investigational New Drug application.

    High risk